Upload
duongkhanh
View
225
Download
3
Embed Size (px)
Citation preview
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
Pfizer Ireland Pharmaceuticals, Pottery Road
Environmental Liabilities Risk Assessment
2010 Review
16 February 2011 Final
49340764 /
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Final
Project Title: Pfizer Ireland Pharmaceuticals, Pottery Road
Report Title: Environmental Liabilities Risk Assessment
2010 Review
Project No: 49340764
Report Ref:
Status: Final
Client Contact Name: Helena Mulvihill
Client Company Name: Pfizer Ireland Pharmaceuticals
Issued By: URS Ireland Iveagh Court 6-8 Harcourt Road Dublin 2 Ireland Tel: + 353 (0) 1 415 5100 Fax: + 353 (0) 1 415 5101
Document Production / Approval Record
Name Signature Date Position
Prepared by
John Grumley
16-Feb-2010 Project Manager
Checked & Approved by
Peter Hassett
16-Feb-2010 Project Director
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Page i
Final
CONTENTS
Section Page No
1. INTRODUCTION.............................................................................................................. 1
1.1 General............................................................................................................................. 1 1.2 Environmental Liabilities Risk Assessments.................................................................... 2 1.3 Basis for the ELRA........................................................................................................... 3 1.4 Key Assumptions.............................................................................................................. 3 1.5 Structure of the ELRA ...................................................................................................... 4 1.6 Limitations ........................................................................................................................ 4
2. OVERVIEW OF PIP ......................................................................................................... 5
2.1 Site Location..................................................................................................................... 5 2.2 Site History ....................................................................................................................... 5 2.3 Site and Process Description of Main Site....................................................................... 7
3. SCREENING AND OPERATIONAL RISK ASSESSMENT .......................................... 13
3.1 General........................................................................................................................... 13 3.2 Complexity...................................................................................................................... 13 3.3 Environmental Sensitivity ............................................................................................... 14 3.4 Compliance Record........................................................................................................ 16 3.5 Risk Category................................................................................................................. 17
4. HISTORICAL ENVIRONMENTAL LIABILITIES ........................................................... 18
4.1 Releases to Air ............................................................................................................... 18 4.2 Releases to Process Water and Surface Water Discharge Sewer................................ 19 4.3 Soil and Groundwater Quality ........................................................................................ 23
5. EXISTING ENVIRONMENTAL CONTROLS AT PIP .................................................... 27
5.1 General........................................................................................................................... 27 5.2 Environmental Management .......................................................................................... 27 5.3 Releases to Atmosphere................................................................................................ 27 5.4 Releases to Surface Water and Groundwater ............................................................... 28 5.5 Emergency Planning/Preparedness............................................................................... 29 5.6 Prevention of Fire ........................................................................................................... 29
6. SITE SPECIFIC ELRA................................................................................................... 31
6.1 General........................................................................................................................... 31 6.2 Methodology-Risk Identification, Likelihood and Consequence .................................... 32 6.3 Identification of Risks at PIP .......................................................................................... 36 6.4 Assessment of Risks at PIP ........................................................................................... 55 6.5 Risk Prevention, Mitigation and Management ............................................................... 58
7. FINANCIAL PROVISIONS ............................................................................................ 64
7.1 Current Financial Provisions .......................................................................................... 64
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Page ii
Final
CONTENTS
Section Page No
7.2 Assessment of Pfizer Financial Provision ...................................................................... 65
8. LIMITATIONS ................................................................................................................ 67
9. COPYRIGHT.................................................................................................................. 67
APPENDIX A - SITE PLAN
APPENDIX B - STATEMENT OF PARENT COMPANY FINANCIAL GUARANTEE
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 1
Final
1. INTRODUCTION
1.1 General
Pfizer Ireland Pharmaceuticals, Dun Laoghaire (PIP) operate a manufacturing facility at
Pottery Road, Dun Laoghaire, Co. Dublin.
PIP was granted an Integrated Pollution Control Licence (Register Number P0019-01 by
the Environmental Protection Agency (EPA) on the 03 October 1995 for the manufacture
of pesticides, pharmaceutical or veterinary products and their intermediates. This licence
was reviewed and replaced by the Integrated Pollution Prevention and Control Licence
(IPPC) (Reg. No. P0019-02) issued by the Environmental Protection Agency (EPA) on
the 14 November 2006 for:
‘The use of a chemical or biological process for the production of basic pharmaceutical
products.’
Clause 12.3 of the IPPC Licence requires the preparation and submittal to the Agency of
an Environmental Liabilities Risk Assessment (ELRA). The specific requirements are as
follows:
12.3.2 The licensee shall arrange for the completion by an independent and
appropriately qualified consultant, of a comprehensive and fully costed
Environmental Liabilities Risk Assessment (ELRA), which addresses the
liabilities from past and present activities. The assessment shall include those
liabilities and costs identified in Condition 10 for execution of the
RMP/CRAMP. A report on this assessment shall be submitted to the Agency
for agreement within twelve months of date of grant of this licence. The ELRA
shall be reviewed as necessary to reflect any significant change on site, and in
any case every three years following initial agreement: review results are to be
notified as part of the AER.
12.3.3 As part of the measures identified in Condition 12.3.1, the licensee shall, to
the satisfaction of the Agency, make financial provision to cover any liabilities
identified in Condition 12.3.2. The amount of indemnity held shall be reviewed
and revised as necessary, but at least annually. Proof of renewal or revision of
such financial indemnity shall be included in the annual ‘statement of
measures’ report identified in Condition 12.3.1.
The EPA Guidance Document entitled “Guidance on Environmental Liabilities Risk
Assessment, Residuals Management Plans and Financial Provision, copyright 2006) – ”
(hereafter referred to the EPA ELRA Guidance Document 2006) was used in the
preparation of this Environmental Liabilities Risk Assessment update in 2010.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 2
Final
1.2 Environmental Liabilities Risk Assessments
Any industrial site has the potential to generate environmental liabilities, i.e. damage to
the environment, which must be remedied, such remediation associated with a
quantifiable financial cost.
Environmental liabilities may arise from anticipated or foreseeable events, i.e. known and
quantifiable releases to the environment, which arise due to the day-to-day operation of
the facility. Examples of such potential liabilities include the long-term management and
aftercare of a tailings pond at a mining or minerals refining site or on-site landfill of waste
materials. For a site subject to IPPC Licensing, regular emissions to air, water and land
has been the subject of detailed quantification and consequence analysis, i.e.
assessment of the impact of emissions, during the licence application process. The
resulting IPPC licence either establishes emission limits and other conditions at levels,
which prevents the arising of new liabilities, or may require bonding or other secure
funding mechanism to cover the expected liability. The latter case applies usually to, for
example, on-site landfill activities.
Environmental liabilities may also arise from unanticipated or unforeseen events. Such
events may be generally classified under the following headings:
• Events which are sudden and which are identifiable as an incident or series of
related incidents which give rise to an environmental liability concurrent with the
incident or shortly thereafter;
• Event’s, which develop gradually or go unnoticed for a long period of time, which
gradually gives rise to an environmental liability.
Examples of the former would include explosion/fire or accidental release of chemicals
from a storage tank to a watercourse.
An example of the latter would be leaks in underground storage tanks or transfer lines,
which would result in the gradual build-up of soil and/or groundwater contamination.
The costs of dealing with unanticipated or unforeseen events are usually issues, which
are addressed in the insurance cover for the industrial site in question.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 3
Final
The Environmental liability risk assessment (ELRA) considers the risk of unplanned
events occurring during the operation of a facility that could result in unknown liabilities
materialising. Based on an initial risk categorisation of the activity into Low, Medium or
High risk, different approaches are recommended according to the risk category. Simple
approaches are proposed for low risk facilities to more detailed site-specific approaches
involving detailed environmental liability risk assessment for higher risk facilities.
1.3 Basis for the ELRA
The basis of this ELRA is as follows:
� Information from the preparation of the original ELRA in 2007.
� A review of changes to the activities carried out at the site since 2007, including
processes and services.
� A review of the following documentation supplied by PIP:
- IPPC License Application Files;
- Annual Environmental Reports for 2008 and 2009;
- Residuals Management Plan review (March 2010); and
- Incident Report Forms for 2007, 2008 and 2009.
� Publicly available information from the EPA.
� URS reports on soil and groundwater management prepared for submission by
Pfizer to the EPA.
� Identification of existing and potential hazards, including evaluation of materials
and wastes generated.
� Consideration of historic environmental incidents and remediation works
undertaken.
Based on the desk-based study research and discussions with the site’s Environmental
Team, a thorough assessment was made of potential environmental liabilities requiring
remediation to which costs could be assigned. Remedial actions are described for these
and remediation or corrective costs are identified.
1.4 Key Assumptions
There is a reasonable degree of subjectivity and uncertainty involved in Environmental
Liabilities Risk Assessment so it is important to identify any assumptions at an early
stage. These are as follows:
� It is assumed that PIP maintains site conditions in accordance with their IPPC
licence (Reg. No. P0019-02) and greenhouse gas emissions permit (Permit No.
IE-GHG155-02). No provision has been made for costs associated with any
criminal proceedings that could arise. It is understood that there is good will and a
strong desire by PIP to remain complaint with relevant legislation and EPA
requirements.
� The ELRA has been based upon historic and current operational activities. It
does not consider potential environmental liabilities associated with significant
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 4
Final
changes in use of the site, such as redevelopment for other commercial or
industrial purposes by PIP or any other party, as these would require a separate
risk assessment exercise should they arise. Furthermore, the financial provision
discussed in this report relates specifically to the environmental risks associated
with historic and current operational activities (excluding the Residual
Management Plan (RMP)). However, the ELRA does make reference to the costs
of the final clean up of the site after closure as this is set out in the sites RMP
(revised March 2010). The RMP is specifically catered for under Condition 10 of
the IPPC License Reg. No. P P0019-02.
1.5 Structure of the ELRA
The ELRA report is structured as follows:
Section 2 provides an overview of the PIP facility including details of existing process,
buildings and structures present on the site at the time this report was prepared.
Section 3 describes the initial screening and operational risk assessment carried out for
the PIP facility.
Section 4 provides an overview of the historical environmental liabilities at the facility.
Section 5 provides an overview of the existing measures in place at the site to minimise
possible environmental liabilities associated with the facility.
Section 6 described the site specific risk assessment, which was carried out for the
facility. It includes section on Risk Identification, Occurrence Likelihood, Severity
Assessment, Risk Evaluation and Prevention/Mitigation.
Section 7 describes the financial provisions in place to deal with any unknown liabilities
and identifies possible gaps between the level of cover provided and the level of risk
associated with the facility.
1.6 Limitations
URS has prepared this report for the sole use of PIP and for submission to the EPA in
accordance with generally accepted consulting practices and for the intended purposes
as stated in the agreement under which this work was completed. No other warranty,
expressed or implied, is made as to the professional advice included in this report.
Unless otherwise stated in this report, the assessment assumes that the site and facilities
continue to be used for their current purpose.
The conclusions and recommendations contained in this report are based upon
information provided by others and the assumption that all relevant information has been
provided by those relevant bodies from whom it has been requested.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 5
Final
2. OVERVIEW OF PIP
2.1 Site Location
The site is located on Pottery Road approximately 3.5km south west of Dun Laoghaire
town centre in County Dublin. A site plan is shown in Appendix A. Surrounding land use
is primarily residential with neighbouring land use as follows:
• East: Light industrial units, a sports ground and some residential properties;
• South: Residential and a “pitch & putt” golf course. A building (at one time an
EPA regional laboratory) is situated approximately 100 m from the east site
boundary. The building is now a motor company service centre;
• West: Pottery Road and across this road, residential properties; and
• North: National Rehabilitation Hospital on extensive grounds which adjoin the
site. Further to the north east, and across Pottery Road, there is a small industrial
estate with a mix of commercial and industrial facilities (approximately 1 km from
the site).
The closest residential properties are those along the south east of the site boundary and
are within 20m of the site boundary.
2.2 Site History
URS retrieved information on site history from:
• Environmental Impact Statement information prepared as part of the 2005 to
2007 site redevelopment project;
• Previous site investigation reports; and
• Residual Management Plan updated in March 2010.
A brief description of the site history is as follows:
• At, or before, 1912 and up to, or before, 1940: 6-inch Ordinance Survey maps
indicate the presence of a sand quarry extending roughly north west to south east
of the site, beginning approximately where the Adams Building was originally
standing;
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 6
Final
• 1940 to 1969: - although this timeframe has not been verified, it appears that the
old sand quarry, now disused, was used to landfill domestic rubbish, thought to
be from ‘the Corporation’ (in reference to Dublin Corporation, a local authority). A
geotechnical investigation undertaken in 1997 concluded that a second phase of
filling occurred when the Adams and PM1 buildings were constructed. The
geotechnical report concluded from soil sampling that there was no evidence to
suggest that this second phase of filling contained domestic waste. Instead, it
was concluded in the 1997 geotechnical report that the fill material was
construction related.
• 1972: Warner-Lambert moved its ethical and consumer products manufacturing
facility from Abbey Road, Blackrock, Dublin to the site at Pottery Road. The
product manufactured was gum base in one building (the Adam’s Building);
• 1973: Manufacturing was expanded in the Adams Building to produce finished
gum. Employment was expanded from 75 to 300 persons;
• 1976: A General Diagnostics Building (the current building called Production
Module 1, or PM1) was constructed and employment expanded to 500 persons.
In this building, Warner Lambert commenced manufacturing of medical
diagnostic reagents;
• 1980: Suites for the manufacture of drug substances Elase and Thrombin were
added to PM1. Aseptic production commenced;
• 1981: Finished gum manufacturing ceased (i.e., manufacturing limited to gum
base);
• 1984: Medical diagnostic reagents manufacturing ceased in PM1;
• 2000: Warner-Lambert was purchased by Pfizer. The Adams Building was leased
out by Pfizer to Cadbury Schweppes. The Warner-Lambert confectionary
businesses were subsequently sold to Cadbury Schweppes;
• 2004: Pfizer purchased 7 acres of land from neighbouring National Rehabilitation
Hospital;
• 2006: Gum base manufacturing ceased and Cadbury Schweppes moved out of
the Adams Building. Later that year the Adams Building was demolished;
• 2005/2007: The site was substantially redeveloped in a site expansion project
(called the Aseptic Expansion Project). The expansion included a new Central
Utilities Building (CUB), production building PM2, Waste Management Building,
Personnel Support Facility Building and Warehouse on the expanded site area;
and
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 7
Final
• 2009: The first commercial batch produced in PM2 was in 2009. The new effluent
treatment system installed in 2007 was also commissioned during this time.
2.3 Site and Process Description of Main Site
The pharmaceutical plant is primarily engaged in the manufacture of sterile
pharmaceutical products. The site currently employs 260 people in the production of a
range of pharmaceutical products. Manufacturing operations normally operates three
shifts, starting at 7am on Monday and ending 4am on Saturday.
Pfizer recently announced its intention so exit operations on a phased basis by 2014.
Table 2.1 below summarises the key site buildings. The balance of the site comprises:
• A complex of smaller structures at the southern end of the site, including offices,
water storage tanks, pump house, a workshop, and a contractors compound. The
site contaminated firewater retention tanks are located there also;
• Main site car-park, roadways and entrance security building;
• A landscaped area in the centre of the site which is the footprint of the former
chewing gum base factory (called the Adams Building). The Adams Building was
demolished in 2006; and
• An Electricity Supply Board of Ireland (E.S.B) substation, built in 2005 that is
identified within the site boundary on the far north end. However, the land on
which the substation is built is owned by the E.S.B. There is a separate
entrance/exit to this substation from Pottery Road, jointly controlled by the E.S.B.
& Pfizer.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 8
Final
Table 2.1: Site Main Buildings
Building Construction
Date
Approx.
area (m2)
Current Main
Use
Description
Production
Module 1
(PM1)
Various 13,000
Bio/Biologics
production,
aseptic filling,
drying and
packaging
This two storey building contains production areas and some of the on-site
laboratories as well as a penthouse plant room. The Biologics Production Area
and Suite 1 are located on the ground floor. Suite 3, the Bioprocess production
area and laboratories (Chemistry and Biologics) are located on the first floor. The
production areas in PM1 are detailed as follows:
• Biologics Production Area: The Biologics Production Area (Bulk) is a non-sterile
processing area used to manufacture Fibrinolysin. Fibrinolysin is an intermediate
product which is used in the preparation of Elase Vials in Suite 3 and
Fibrinuclease Powder in Suite 1.
• Suite 1: Suite 1 is a dedicated facility used for filling, lyophilisation (freeze
drying) and packaging of Fibrinulcease powder. Fibrinulcease powder is a bulk
freeze dried powder which is exported to PIP affiliates for further processing to
Elase ointment.
• Suite 3: Suite 3 is used for aseptic formulation and filling, lyophilisation (as
appropriate) and packaging of sterile products. Suite 3 is operated as a multi-
product facility. Suite 3 produces the following products: Ketalar, Ketanest S,
Elase, Cerebyx, Vfend, Azithromycin and Fosfluconazole.
• Bio-Process Production Area: the Bio-Process production area, which was
previously the Biotech Suite, is used for the purification, filling and lyophilisation
(as appropriate) of pegylated products. It is currently used for the manufacture of
Macugen and Pegvisomant.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:04
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 9
Final
Building Construction
Date
Approx.
area (m2)
Current Main
Use
Description
Production
Module 2
(PM2)
2006/2007 6,878 Aseptic filling
and packing
This is two storeys high with penthouse plant rooms. The production area is
located on the first floor and plant rooms are located on the ground floor as well
as the penthouse. The production area within PM2 is used for aseptic formulation
and filling, lyophilisation (as appropriate) and packaging of sterile products. PM2
is also operated as a multi-product facility. PM2 currently produces the following
products: Azithromycin, Vfend and Somavert.
Warehouse 2006/2007 5,386
Raw material
and finished
production
storage
including a large
Quarantine
compound
Stores the majority of dry solid raw materials that arrive on-site. Some final
product is also stored in the warehouse prior to shipping off site.
Personnel
Support
facility (PSF)
2006/2007 3,780
Offices/laborator
ies, canteen and
staff facilities
The PSF is two storeys high with a penthouse plant room. The canteen is located
on the ground floor and laboratories including the Microbiology Laboratory and a
HPLC Laboratory are located on the first floor.
Central
Utilities
Building
(CUB)
2006/2007 2,121
Provision of key
utilities to
production
buildings
(steam,
compressed air,
cooling water)
A two storey high building contains various utilities such as boilers, chillers, air
compressors and transformers.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 10
Final
Building Construction
Date
Approx.
area (m2)
Current Main
Use
Description
Waste
Management
Building
2006/2007 Approx 150
Waste
Autoclaving
Final waste load
preparation.
Comprising of tank storage and waste/chemical storage areas.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 11
Final
There is an underground utilities tunnel linking the pump house located on the far south
end of the site and the PM1 building. A link corridor links the PSF building and PM2.
A pipe rack connects the CUB with the production facilities and warehouse.
The process wastewater balance tanks (2 No.) are located east of building PM1. There is
an older wastewater treatment balance tank and associated sub-surface pump sump
located south of PM1. However, the latter wastewater treatment infrastructure is no
longer used.
The other main features of the site are as follows:
• Switch Room;
• Security Gatehouse;
• Cooling Towers; and
• Nitrogen Pad.
2.3.1 Ancillary Operations
Ancillary operations associated with the production facilities are detailed below:
2.3.1.1 Ultra Pure Water Systems
Ultra pure water is one of the most important plant services; it is used in all stages of the
production and analysis in the production plant. Ultra pure water is circulated throughout
the main pharmaceutical buildings supplying all production areas and laboratories. The
process for producing ultrapure water involves passing potable water through a variety of
filtration steps.
2.3.1.2 WFI (Water for Injection) Systems
The WFI Systems (x3) supplies Suite 3, PM2 and Bio-Process production. WFI is
produced by generating steam from the purified water and then condensing this steam.
The condensate is then distributed to the production areas as WFI.
2.3.1.3 CIP/SIP Systems
Clean in Place/Steam in Place (CIP/SIP) system is used to clean the product holding and
mixing tanks, filling lines, filling pumps, filling needles and all product transfer lines. The
CIP system involves rinsing the tanks and lines with purified water, WFI orthophosphoric
acid and sodium hydroxide solutions. Upon completion of the CIP, the entire system is
steam sterilised in place (SIP) using clean steam.
2.3.1.4 Glycol Systems
The plant is equipped with chilled glycol systems. These systems supply all production
areas with glycol at -6oC to facilitate product cooling. At various points throughout the
plant the glycol can be reheated and used as a heating medium.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 12
Final
2.3.2 Manufacturing Activities
The main manufacturing activities on site include:
• Bio-pharmaceutical production of active pharmaceutical ingredients (APIs) by
extraction of proteins in a fractionation process;
• Non-sterile pharmaceutical product production formulation and filling; and
• Aseptic formulation filling: - APIs from other Pfizer sites are compounded in
aqueous solutions, sterile filtered and filled into sterile glass vials. Downstream
processing includes freeze drying (lyophilisation), and packaging.
Production does not involve chemical reactions.
The main final products are summarised in Table 2.2, below.
Table 2.2: Summary of Main Site Products
Brand Name Active Product Benefit
VFEND Voriconazole Anti Fungal
Zithromax Azithromycin Antibiotic
CerebyxB Fosphenytoin Anti Epileptic
Prodif Fosfluconazole Anti Fungal
Ketanest/Ketalar Ketamine General Anaesthetic
Elase Fibrinolysin Wound Healing
Somavert Pegvisomant Growth Hormone Inhibitor
Macugen Pegaptanib Sodium Macular degeneration
Most of the products are manufactured to final product status. Some products are
finished in other Pfizer sites worldwide. Batch sizes vary to product and range from
approximately 19 to 82,500 vials per batch.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 13
Final
3. SCREENING AND OPERATIONAL RISK ASSESSMENT
3.1 General
As a starting point in the process, a relatively simple risk assessment decision matrix can
be used to classify sites into Risk Categories (1-3) and thereby select the specific ELRA
and Financial Provision (FP) requirements that will be needed. The risk assessment
decision matrix outlined in the EPA ELRA Guidance Document 2006 was used.
The risk category assigned to the facility depends on the complexity of operations at the
site, the environmental sensitivity of the receiving environment and the compliance record
of the facility.
• Complexity – the extent and magnitude of potential hazards present due to the
operation of the facility (e.g. a function of the nature of the activity, the volumes of
hazardous materials stored on site etc.). A Complexity Band (G1 least complex to
G5 most complex) for each class of activity has been assigned and included in a
Look-Up Table (Appendix B of the EPA ELRA Guidance Document 2006).
• Environmental Sensitivity – the sensitivity of the receiving environment in the
vicinity of the facility, with more sensitive locations given a higher score (e.g. the
presence of aquifers below the site, groundwater vulnerability, the proximity to
surface water bodies and their status, the proximity to sensitive human receptors,
etc). The environmental sensitivity is calculated on a site-specific basis using a
sub-matrix (Table 3.1).
• Compliance Record – the compliance history of the facility.
Each aspect is multiplied to give the Total Score for the facility, and this can be used to
place the facility into an appropriate risk category as follows:
• Risk Category 1 = Score < 5
• Risk Category 2 = Score 5 - 23
• Risk Category 3 = Score = > 23.
Once this has been completed, the licensee proceeds through the relevant steps of ELRA
and FP that are considered appropriate for the risk category.
3.2 Complexity
A look up table for Irish activities has been included in Appendix A of the EPA’s ELRA
Guidance Document 2006.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 14
Final
The Complexity Band is used to determine the value used in the Operational Risk
Assessments as follows:
G1 = 1, G2 = 2, G3 = 3, G4 = 4 and G5 = 5
In 14th November 2006, PIP was granted a revised IPPC License (Registration No.
P0019-02). The relevant complexity band for PIP according to the EPA’s ELRA Guidance
Document 2006 is as follows:
• IPPC activity class 5.16: the use of a chemical or biological process for the
production of basic pharmaceutical products.
PIP produces approximately 200 tonnes of finished product and intermediate annually,
which is less than 2000 tonnes per annum and therefore has been assigned a complexity
band G3 and receives a score of 3 according to the ELRA complexity banding.
3.3 Environmental Sensitivity
A sub-matrix for environmental sensitivity is outlined in Table 3.2. This considers 6 key
potential environmental receptors and assigns individual scores that are added together
to arrive at a total environmental attribute score. The scoring system used is outlined in
EPA ELRA Guidance Document 2006. The total environmental attribute score is used to
look up the environmental sensitivity classification in Table 3.1 below. The environmental
sensitivity sub-matrix has been developed based on professional judgment and with
reference to the system designed in the EP OPRA Scheme by the Environment Agency
(UK). The environmental sensitivity classification is used in the operational risk
assessment to calculate the total score.
The key receptors include:
• Human occupation;
• Groundwater protection;
• Sensitivity of receiving water;
• Air quality & topography;
• Protected ecological sites; and
• Sensitive agricultural receptors.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 15
Final
Table 3.1 Environmental Sensitivity Classification
Total Environmental Attribute Score Environmental Sensitivity Classification
Low <7 1
Moderate 7-12 2
High >12 3
Table 3.2: Environmental Sensitivity Sub-Matrix
Environmental Attribute Environmental
Attribute Score Note 1, 2
Human Occupation
<50m
50m-250m
250m–1,000m
>1km
5
3
1
0
Groundwater Protection
Regionally Important Aquifer
Locally Important Aquifer
Poor Aquifer
Vulnerability Rating – Extreme
Vulnerability Rating – High note 3
Vulnerability Rating - Moderate
Vulnerability Rating - Low
2
1
0
3
2
1
0
Sensitivity of Receiving Water
Class A
Class B
Class C
Class D
Designated Coastal & Estuarine Waters
Potentially Eutrophic Coastal & Estuarine Waters
3
2
1
0
2
1
Air Quality & Topography
Complex Terrain
Intermediate Terrain
Simple Terrain
2
1
0
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 16
Final
Environmental Attribute Environmental
Attribute Score Note 1, 2
Protected Ecological Sites
Within or directly bordering protected site
<1km to protected site
>1km to protected site
2
1
0
Sensitive Agricultural Receptors
<50m from site boundary
50m-150m from site boundary
>150m from site boundary
2
1
0
Note 1 – The environmental attribute which is relevant to the PIP facility is underlined and bold. Note 2 – The scoring system used is taken from the EPA ELRA Guidance Document 2006.
Based on the above environmental sensitivity sub-matrix, the total environmental attribute
score for PIP is 8 which indicates that that the environmental sensitivity classification for
the site and surrounds is 2.
3.4 Compliance Record
The compliance record score is derived from the compliance history of the facility and
whether the activities carried on resulted in contamination or pollution.
For newly licensed facilities and those operating without non-compliance of emission
limits, then these are classified as Compliant/New Facility and have a score of 1.
Licensed facilities with administrative non-compliances only are classified as
administrative non-compliant and have a score of 2.
Licensed facilities with minor non-compliances (< 5 non-compliances in 12 month period)
are classified as being Minor Non-Compliant and have a score of 3. Facilities with minor
soil and groundwater contamination (i.e. those with concentrations above background but
not posing risk to the environment) are also considered in the class.
Licensed facilities with major non-compliance history (≥ 5 non-compliances in 12 month
period) and/or those with significant soil and groundwater contamination (i.e. requiring
remediation and/or long-term monitoring requirements) are classified as Major Non-
Compliant/Significant Ground Contamination and have a score of 4.
Those facilities with repeated non-compliances (>10 Total) during a 12-month period are
classified as Repeat Non-Compliance and have a score of 5.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 17
Final
As part of the preparation of this ELRA, documentation relating to IPPC Licence
compliance and prosecutions was examined. This documentation review demonstrated
that the site has a good record of compliance with the Conditions of the IPPC Licence. In
the last three years, there have been 4 non-compliances with the IPPC Licence. These 4
non-compliances are related to ELV exceedance for emissions to sewer.
In addition to the above non-compliances, the site is carrying out a separate investigation
into trichloroethylene levels in groundwater as detailed in section 4.3.2. This investigation
has been conducted with EPA oversight since 2005.
Between January 2008 and January 2011, the site received a total of 3 complaints. In all
cases the site resolved these issues.
Although there is a very good history of compliance at the site with regard to the IPPC
Licence, a compliance record score of 4 is judged appropriate for the site due to the
historic soil and groundwater contamination issue.
3.5 Risk Category
The proceeding subsection of this section has determined the:
• Complexity Score (G3) = 3
• Environmental Sensitivity Score = 2
• Compliance Record Score = 4
The product of these scores is used to calculate a total score, which is then used to
assign the site specific risk category (Table 3.3). The product of the above scores is 24,
which according to Table 3.3 below indicates that a risk category of 3 is applicable to the
PIP site.
Table 3.3 – Risk Category
Risk Category Total Score
Category 1 <5
Category 2 5-23
Category 3 >23
The PIP site is classified in risk category 3 and therefore the guidance provided in the
EPA ELRA Guidance Document 2006 for high-risk facilities was used when carrying out
this assessment.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 18
Final
4. HISTORICAL ENVIRONMENTAL LIABILITIES
4.1 Releases to Air
With regard to sudden and accidental releases to air, there is no history of:
� Major fires or explosions at the site;
� Run-away reactions resulting in significant discharge to atmosphere; and
� Significant accidental releases of hazardous gases.
Consulting the Annual Environmental Reports, the monitoring results for emissions to
atmosphere were examined for 2007, 2008 and 2009.
Owing to the nature of production and low organic solvent usage, the site is not regulated
under the Emissions of Volatile Organic Compounds from Organic Solvents Regulations
2002 (S.I. No. 543 of 2002).
In an annual audit report in 2009, the EPA raised a non-compliance related to a reported
volumetric flow rate of emissions to air from emission point A2-1. In response to the
alleged non-compliance, the site undertook an investigation into the alleged non-
compliance and concluded that the results obtained were not valid, due to the location of
the sample port. Independent verification of the extract fan rating demonstrated that the
fan is a fixed speed fan. Additional extraction flow rate monitoring was undertaken by a
third party and this testing demonstrated that the volumetric flow rate was below the
licence emission limit value.
Fugitive emissions are largely generated in the following operations on the site:
• Wastewater treatment;
• Bulk storage tank filling; and
• Building ventilation.
The site undertook an internal risk assessment on fugitive emissions in 2007. The
assessment covered leak detection on the catchment system specified in the IPPC
licence condition 3.12 and the IPPC licence condition 6.9 on reducing fugitive emissions.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 19
Final
The assessment considered various activities, mainly filling diesel tanks, acid and caustic
tanks, chloroform dispensing, solvent handling and waste handling. Using a risk scoring
system, the site concluded that there is a negligible risk to the environment from fugitive
emissions with a very low potential to generate substantial fugitive emissions. Therefore,
the site concluded that no additional controls for fugitive emissions were required.
Based on a review of the historical data for the facility, there is no evidence to suggest
that releases from the site to air have resulted in the development of any off-site
environmental liability.
4.2 Releases to Process Water and Surface Water Discharge Sewer
4.2.1 Overview
With regard to sudden and accidental discharges, there is no history of:
� Major fires or explosions at the site resulting in significant discharges of firewater;
� Significant failure of the WWTP treatment process; and
� Significant accidental releases of wastewaters in exceedence of the ELV
specified in the sites previous IPC/IPPC Licences.
There are two types of wastewater generated on-site:
• Process effluent; and
• Sanitary wastewater.
Each type of wastewater is conveyed and managed in a separate drainage system on the
site. However, both wastewater streams discharge to the same Dun Laoghaire Rathdown
County Council foul sewer drain that runs along Pottery Road. This sewer connects up
with the main Council sewer network that in turn discharges to the Shanganagh
Treatment Works. The treatment works is located approximately 3.5 km south east of the
site in the town land of Shanganagh.
The Shanganagh Treatment Works is currently being upgraded. Earlier in 2010, the first
main phase of the treatment works upgrade was completed to provide a replacement
preliminary treatment plant (screening and grit removal). Site management informed URS
that it is planned by the local authorities to continue to upgrade the treatment works to
provide secondary wastewater treatment (activated sludge) and sedimentation,
scheduled for commencement in June 2011. The Shanganagh Treatment Works
discharges to Killiney Bay through a 1.7 km long sea outfall.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 20
Final
4.2.2 Surface water
Surface water, emissions from the site consists of rainfall runoff from roofs, site hard
standing areas and car park areas.
Records evaluated from 2007 - 2009 indicate that there have been no compliance issues
with surface water within that period.
On 5th March 1988, an estimated 3200 litres of diesel oil were spilled inside the pump
house to the south of the site1. The incident occurred whilst topping up diesel header
tanks inside the south wall of the pump house. The tanks are still in place and are used to
supply the sprinkler system supply pumps. Some of the spilled diesel was recovered into
drums in the pump house but the majority of the diesel got out into the main surface drain
running east to west down the access road adjacent to the pump house.
It is thought by site management that diesel (quantity not recorded or estimated) entered
the open stream (the Deans Grange stream) behind Little Meadow Estate.
The surface drain pipe and area were cleaned with detergent and soaked up. The
manhole near the road was pumped clean. All surface water and sewerage drains were
filled in with concrete in the area of the pump-house. A sump was created instead to
capture water or diesel spills.
Warner Lambert was prosecuted in the District Court due to the spill which closed the
matter with relevant authorities at the time.
4.2.3 Process Effluent
Process effluent, or wastewater, results from:
• The cleaning of process equipment;
• The washing of vials;
• The washing of floor and wall surfaces; and
• The protein extraction fractionation process in the biologics production area
(dilute quantities of bovine serum and ammonium sulphate).
Equipment is washed mainly with hot water, caustic and detergent (via Cleaning in Place
systems), or isopropyl alcohol. Floor and wall washings contain detergent or disinfectant.
The steam boilers, purified water and water for injection production systems, freeze
dryers, cooling towers and chillers produce wastewater streams. This wastewater
contains dissolved salts as well as residues of proprietary chemical formulations used to
treat the boiler and cooling water.
1 Short technical report from Mr. Kevin Delaney of Warner Lambert dated 28 April 1988.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 21
Final
The following summarises the process effluent conveyance system:
1. Process effluent from the CUB and the warehouse is drained underground to a
pump sump located halfway along the east boundary wall of the warehouse (the
‘south road sump’). From there, the wastewater is pumped via level control
above ground directly to the two main above ground balance tanks (210,000
litres each);
2. Process effluent from PM2 drains to a centrally positioned sump (the PM2 sump)
and from there is pumped on level control above ground to the two main above
ground balance tanks (210,000 litres each);
3. A similar arrangement is in place for the PSF building (via a PSF sump);
4. Process effluent from the PM1 building is gravity fed to the PM1 tunnel sump, a
series of three fibreglass above ground tanks located inside the utility tunnel
between the pump house and PM1. This effluent stream is then pumped above
ground to two large above ground balance tanks (each 210,000 litres in
capacity) located outside the east wall of the PM1 building;
5. In each of the two balance tanks, the effluent is neutralised by the addition of
acid or caustic soda as necessary from an adjacent pair of AST’s. The balance
tanks are agitated and are run to maximise the usage of acid and caustic content
of the Cleaning in Place solutions that are present in the incoming wastewater.
This minimises the need for additional effluent pH correction;
6. The process wastewater is discharged from the balance tanks by gravity. This
flow is monitored by a dual pH probe system, a flow meter and a control valve at
the tank discharge to control the pH and flow to within IPPC licence limit values.
If an excursion from limit values is identified, the flow is automatically stopped;
and
7. The drained effluent passes through a final effluent sump (licensed emission
point SE1) located just inside the south access gate to the site. There is a
refrigerated composite sampler and pH monitoring system at that sump.
All sample non-continuous analysis is conducted by an external laboratory. Site
management reports emissions data annually to the EPA and quarterly to Dun Laoghaire
Rathdown County Council as required in the site’s IPPC licence.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 22
Final
URS notes that mass loading of contaminants to the receiving Council sewer is low.
Referring to Annual Environmental Reports to the EPA prepared by site management
(2007, 2008 and 2009), the following is a summary of excursions from emission limit
values:
• 2007: 2 excursions, one regarding pH and the other sulphate;
• 2008: 3 excursions, 2 of them due to pH and the third non-conformance with total
daily flow; and
• 2009: 1 excursion due to pH.
In all cases of excursion, the excursion was short in duration and with specific faults
identified and corrective action immediately taken.
Trace concentrations of Chloroform are identified in routine sampling of the process
effluent due to the use of Chloroform in the Elase process in PM1.
In April 2010, the site reported to the EPA an incident where 268 kg of the product
VFEND was discharged through emission point SE1 to the Council sewer. The
investigation undertaken by site following the incident (Site report to EPA dated 27 May
2010) concluded that the concentrations of VFEND in the Council sewer were not
deemed environmentally significant at the receiving Shanganagh Treatment Works.
Toxicity testing of the effluent is undertaken quarterly and compared with the IPPC
licence emission limit value for toxicity of effluent of 10 Toxic Units (TU). The toxicity
testing results for 2009 is summarised in Table 4.1.
Table 4.1: Summary of 2009 Effluent Toxicity Testing
Test Parameter Result (TU)
48 hr LC50 to Tishe battagliai <3.1
15 min EC50 to Vibrio fischeri <2.2
5 min EC50 to Vibrio fischeri <2.2
The EPA periodically takes composite samples from the site effluent monitoring station.
Analysis reports from the EPA demonstrate compliance with SE1 emission limit values.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 23
Final
4.2.4 Sanitary Wastewater
Sanitary wastewater arises from:
• The changing rooms in the PSF;
• Toilets throughout the site; and
• The on-site canteen.
Sanitary wastewater is gravity drained from various buildings on the site in an
underground drainage system. The sanitary wastewater then combines with the process
effluent downstream of the final effluent sump, i.e. downstream of emission point SE1.
From there the sanitary wastewater flows into the Dun Laoghaire Rathdown County
Council sewer on Pottery Road.
There is a grease trap just west of the PSF building to remove grease products from the
canteen wastewater. The grease trap is serviced regularly on contract.
4.3 Soil and Groundwater Quality
4.3.1 Background
Several ground investigation assessments have already been completed at the Pottery
Road site including a site wide soil investigation by Kirwan during 1969-19742, a soil
investigation of made ground on the site by Irish Geotechnical Services Ltd (IGSL) in
19973 and an investigation in the northern portion of the site in 2003
4. In addition, URS
completed soil and groundwater investigations of the southern portion of the site in 2005
and 2006 (as discussed in Section 4.3.2). Because of these and of on-going groundwater
monitoring required under the terms of the current IPPC licence, the quality of the soil
and groundwater beneath much of the site has been well characterised.
2 Kirwan, R.W. (1974) Report on Site Investigation at Pottery Road, Cabinteely for C.H.Clifton, Esq., Trinity College Dublin for
Site Investigations Ltd.
3 Irish Geotechnical Services Ltd (1997) Report on Ground Investigation at Warner Lambert Ltd., Pottery Road, Dun Laoghaire,
IGSL Report 4050.
4 Irish Geotechnical Services Ltd (2003) Report on Site Investigation for Pfizer, Pottery Road, on Behalf of Jacob’s Engineering,
IGSL Report 9230.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 24
Final
4.3.2 TCE Works at the Site
A significant body of information on works relating to TCE investigation and assessment in soil
and groundwater at the Site is available in the EPA Enforcement files for P0019-02 in the form
of correspondence and investigation reports. Key enforcement records are referenced as
footnotes in this summary. Pfizer Ireland Pharmaceuticals has recently submitted a detailed
TCE Work Plan to EPA Enforcement which addresses remediation activities proposed and
future monitoring requirements, including timelines. References as appropriate to the TCE
Work Plan are made in this summary document.
During excavation works at the Site conducted as part of utility services installation in late
2005, visual staining was observed at the base of a shallow in-filled trench, at a depth of
approximately one metre. Analysis indicated that the stained soils contained TCE. Impacted
soils encountered during this excavation were removed and ultimately disposed off-Site at an
appropriate facility. Consequently an assessment of the presence of TCE in soil and
groundwater at the Site was undertaken by URS in October 20055. The assessment included
a soil vapour survey, drilling soil bores and construction of groundwater monitoring wells down
gradient of the trench where TCE was initially reported as detected. The results of this
assessment were submitted to the Environmental Protection Agency (EPA) on 5 January
2006.
A second assessment was undertaken in June 20066 and included additional soil sampling up
gradient of where TCE was first identified and further delineation of TCE in groundwater at the
Site. The findings indicated TCE presence in some of the shallow soils; however, the
concentrations observed did not indicate a significant TCE source to be present with Site soils.
Additional groundwater investigations were completed in 2007. The investigation findings,
Site conceptual Site model (CSM), and the Detailed Quantitative Risk Assessment (DQRA)
are presented in the document Detailed Assessment of TCE in Groundwater7. The DQRA
developed site specific assessment criteria (SSAC) for concentrations of contaminants of
concern in soil, groundwater and soil vapour, which represent theoretical concentrations below
which the risks posed by contaminants to the receptor are no longer significant.
In late 2009, additional soil, soil vapour and groundwater data were collected for additional
characterisation as requested by the EPA. The findings were provided in an Additional
Characterisation (AC) report8. The additional information was used to update the DQRA. This
5 Assessment of TCE in Soil and Groundwater, Pfizer, Pottery Road, Dun Laoghaire, Final Issue No 1, January 2006.
6 Additional Assessment of TCE in Soil and Groundwater and QRA, Pfizer, Pottery Road, Dun Laoghaire, Final,
Issue No 3, February 2007.
7 Detailed Assessment of TCE in Groundwater, Pfizer Ireland Pharmaceuticals, Final, March 2008, Issue No.3.
8 Additional Characterisation of TCE in Soil and Groundwater – Pfizer Ireland Pharmaceuticals, Pottery Road,
Dun Laoghaire (URS, December 2009, reference 49341800).
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 25
Final
report also contained a summary of the proposed remediation strategy for the Site9, which
outlined Insitu Enhanced Bioremediation (ISEB) as the selected remedial technology. This
approach was agreed in principle by the EPA in May 2010.
A pilot study was undertaken in October 2009 to demonstrate the feasibility of the selected
ISEB remedial approach. The findings of the pilot study indicated that injection of carbon
substrate in the bedrock via injection wells is a feasible and effective approach.
4.3.3 Proposed Remediation
Following the successful pilot trial, a Full Scale Remedial Design and Implementation Work
Plan (RD&IMP) has been prepared for the Site10
. This Work Plan details how the remediation
will be implemented and is presented as follows:
(a) Site History;
(b) Remedial Standard & Remedial Objectives;
(c) Remedial Design & Implementation;
(d) Monitoring, assessment, and reporting program and frequencies; and
(e) Contingency actions.
The work plan identifies the following remedial actions to address the Chlorinated Aliphatic
Hydrocarbon (CAH) concentrations observed in groundwater and soil vapour at the Site:
• Perform remediation to reduce concentrations of TCE and its daughter products
through the most practical means available consistent with Best Available
Treatment principles.
• Focus the active remedial effort towards the area where most of the mass of CAH
contamination is considered to lie, and where the greatest reduction in
contaminant mass can potentially be achieved.
• Use a combination of active on-Site remediation and long term monitored natural
attenuation remediation to decrease TCE concentrations at the Site, using the
SSAC as long-term remedial targets.
• Continue both groundwater and soil vapour monitoring at the Site, through both
near term and long term monitoring programmes, to track biodegradation and
natural attenuation mechanisms that are occurring and maintain confidence that
9 Revised Remedial Proposal Summary – Appendix A to Additional Characterisation of TCE in Soil and
Groundwater – Pfizer Ireland Pharmaceuticals, Pottery Road, Dun Laoghaire (URS, December 2009, reference
49341800).
10 Full Scale Remedial Design and Implementation Work Plan, Pfizer Pottery Road, Dun Laoghaire, Co. Dublin,
(URS, February 2011)
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 26
Final
risk-based levels of constituents of concern in groundwater and soil vapour are
below acceptable limits.
The work plan also identifies contingency measures that would be performed, as necessary, if
groundwater or soil vapour monitoring detections are above the SSACs in the Site boundary
compliance wells.
The following monitoring programmes are proposed in the work plan:
The short term groundwater and soil vapour monitoring programme will commence four to six
weeks after the full scale injection event.
These monitoring events will continue on a quarterly basis to verify that the substrate has
been distributed throughout the treatment area and to measure the level of CAH degradation
that is occurring.
Once the Short Term Monitoring break point criteria (detailed in the work plan) have been met,
the long term monitoring programme will commence.
The long term monitoring program will consist of bi-annual monitoring events.
Reports will be issued on an annual basis describing the findings of the long-term monitoring
works. The Long Term monitoring programme (including wells sampled, monitoring frequency
and analytical parameters) will be reviewed with the EPA as required with a view to
decreasing either the number of wells sampled or frequency of sampling on the basis of
results in a given well.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 27
Final
5. EXISTING ENVIRONMENTAL CONTROLS AT PIP
5.1 General
The PIP Dublin Sterile Products Facility at Dun Laoghaire is equipped with a high level of
environmental protection. Ongoing care for the environment is demonstrated by the
continuous upgrading of environmental protection systems/practices, and the continuous
reduction of plant emissions to the environment. It has a programme of continuous
improvement for a mature facility through training of people to maintain good
environmental practices and replacement, upgrading, retro-fitting, and as needed of
equipment to keep abreast of technological improvements.
5.2 Environmental Management
PIP operates an integrated approach to the management of environmental, health and
safety aspects of the site and Environmental Protection has always been a key
consideration. Since 1995, the site has operated under the IPC and IPPC licensing
system.
The management system undertakes regular monitoring of emissions to legal and
regulatory requirements and best practices. This environmental management system is
based on a combination of technical measures and documented environmental
management programmes and procedures, whose objectives are:
• Complying with all the requirements of the site’s IPPC licence,
• Eliminating the risk of accidental events which could give rise to significant
releases to the environment, and
• Ongoing continuous improvement of site environmental performance.
5.3 Releases to Atmosphere
Monitoring of emissions is undertaken for the site boilers and from the Fibrinolysin
process in accordance with IPPCL requirements. The licence also lists 23 minor emission
points and assigns specific emission limits for each of these minor emission points. Site
management is not required to monitor the minor emission points nor report monitoring
results to the EPA.
Emission point A2-1 has an activated carbon (charcoal) abatement system connected to
the Elase process equipment train. This is so as to remove Chloroform that may be
entrained in process air extraction. The adsorbent carbon is routinely checked for
saturation and replaced as required. The waste carbon is stored in a secure chemical
storage cabinet next to the pump house awaiting off-site disposal.
For further information on releases to air is detailed in Section 4.1.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:05
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 28
Final
5.4 Releases to Surface Water and Groundwater
5.4.1 General
The surface water from each of the branches passes through an oil/water interceptor
before combining in the far south west corner of the site (near emission point SE1). The
interceptors are inspected weekly and drained by a contractor if significant oil/petroleum
contamination is identified.
The surface water is conveyed from the site in a dedicated surface drain system. There
are two main branches to the system:
1. The northern part of the site (relative to Plant North) serving mainly the
warehouse, PM2 and surrounding hard standing; and
2. The southern part of the site (relative to Plant north) serving the rest of the site.
All of the site clean surface water drain flow (default) passes through a monitoring
chamber via IPPC licensed emission point SW1. The surface water ultimately discharges
to the Deans Grange stream located approximately 100 m west of the site.
Once per week, a grab sample of the surface water is taken and tested for COD in an
external laboratory. In addition, the flow in the chamber is inspected daily for odour and
colour. Sample analysis data is reported annually to the EPA.
Surface water from the northern part of the site passes through a sub-surface surge tank
(volume 216,000 litres) and surface water from the southern part of the site through a
similar sub-surface tank located just in front of the Security Building (volume 460,000
litres). These surge tanks that there is no sudden surge of surface water to the receiving
Deans Grange stream.
The combined surface water flow passes through a monitoring chamber where the pH is
continuously monitored. If the pH steps outside the range pH 6.5 to 8.5, a diversion valve
automatically closes. The surface drain monitoring chamber then overflows to nearby
sub-surface re-enforced concrete surface water pump chamber (called the Fire Water
Collection Sump). From this sump, the collected surface water is pumped on level control
to one of the two 725 m3 above ground circular bolted steel firewater retention tanks
located at the south end of the site, the total retention volume being 1725 m3. Once
contained in these tanks, the collected surface water can be sampled and either pumped
to the process effluent balance tanks or off-site in contractor tankers.
The same surface water diversion procedure would be undertaken in the event of a fire
on the site. The previously mentioned diversion valve will also automatically close in the
event of either fire pump activation or on detection of flow through the sprinkler system.
The main potential sources of contamination of the surface water, soils and groundwater
are spills or leaks of raw materials, intermediates, final products, process wastes or fuels
from material and waste storage locations on site.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 29
Final
Bulk storage tanks on site are located above ground and provided with concrete bunds to
contain any spills of leaks. The bunds are not connected to the surface water drainage
system. There are no underground tanks on site. Similarly chemicals and liquid wastes
are stored in 200 litre drums or smaller containers, located in designated bunded areas
within the plant. Site roads, truck unloading/loading yards and hard standing areas are
paved and rainfall run-off is collected into the surface water system.
The surface water discharged from the site is monitored continuously for pH by
monitoring equipment installed in the outfall chamber. Monitoring of surface water and
calibration of associated monitoring equipment is controlled by the site SOP EHS-201-06
IPPC Licence Compliance.
Process effluent from the different sources on site drains by gravity to a collection sump
from where it is pumped above-ground to the effluent balancing tanks. The effluent
balancing tanks control the effluent characteristics and flow volume to meet the IPPC
licensed limits. The effluent is balanced and neutralised if necessary using acid and
caustic dosing, prior to discharge. The final effluent sump is fitted with a pH monitor and
a refrigerated sampler. The process effluent is then combined with the sanitary effluent
and discharged to the Dun Laoghaire-Rathdown County Council sewer.
Operation of the effluent treatment system is automatically controlled by the Building
Management System (BMS). This system is alarmed for a series of events/parameters,
which indicates if there is a malfunction of operating equipment within the plant. In the
event of the occurrence of an alarm, this alarm is relayed to the site security gatehouse,
which is manned 24 hours a day. These alarms are then immediately relayed to members
of the EHS and Utility Departments upon occurrence, so that the operation of the plant
can be investigated.
5.5 Emergency Planning/Preparedness
PIP maintains an Emergency Response Procedure. Emergency Response Objectives,
Action Plans and Responsibilities are set down in the Procedure.
Detailed action plans are included in the procedure which specifies pre-planned
emergency response actions for several potential emergency situations. An Emergency
Planning Committee advises on the overall site strategy for handling emergencies, testing
the site capabilities and interfacing with local emergency services.
Emergency drills test the effectiveness of the plan and are carried out regularly. Desk top
exercises are also carried out regularly and various scenarios are presented to the
participants. A critique of the exercise is completed afterwards.
5.6 Prevention of Fire
5.6.1 Procedures
The plant Emergency Procedure specifies the action to be taken by employees on
discovering a fire. This includes, sounding fire alarms, evacuation requirements and
notifying the Dun Laoghaire Rathdown County Council Chief Fire Officer. Fire prevention
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 30
Final
is emphasised by audits, hot work permit restrictions and Fire Prevention Notices.
Operation instructions and Material Safety Data Sheets specify emergency response
requirements for fire or spill control.
5.6.2 Training
Fire training sessions are held regularly. The training covers practical fire extinguishers
operations, a review of plant emergency plans for handling fire situations and fire
prevention training. Fire evacuation drills are held regularly to familiarise employees with
evacuation requirements and that head counts are completed effectively.
5.6.3 Emergency Crew
The Emergency Response team provides assistance in dealing directly with the incident
and bringing the situation under control. The team is specifically trained in responding to
emergencies which may arise in PIP Dublin, the equipment available to deal with
incidents and the actions required to be taken.
5.6.4 Storage and Handling of Hazardous Materials
The plant has been designed and is operated in such a manner as to minimise the risk of
fire or explosion in the storage and handling of flammable materials. The nature of
manufacturing at the site is such that large scale bulk storage of chemicals is not
necessary. Flammable materials are confined to above ground storage tanks. Most of the
hazardous substances are both delivered to site, and stored on site, in various packaging
(primarily UN approved metal and plastic drums of varying volume, UN approved fibre
kegs and glass bottles). The site maintains Safety Data Sheets (SDSs) in an electronic
library and also in hard copies. The site has a licence for the storage and use of a
controlled substance, Ketamine, used for the production of Ketalar (a general
anaesthetic).
5.6.5 Management of Fire Safety
Measures are in place on the site to prevent fires and emergency situations and to
mitigate the effects of an incident. Specifically:
• Where required, buildings are sprinkler protected, i.e. in all areas where
flammable liquids are stored and handled such as the warehouse;
• There are fire hydrants located on the site in strategic locations;
• There is a comprehensive fire detection and alarm system throughout the site;
• Weekly checks are undertaken on various fire protection systems;
• There is a 1.6 million litre firewater/service water storage tank to the south of the
site;
• There are two emergency generators on the site;
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 31
Final
• There is 24 hour security on the site including night time and weekend Site
inspection rounds and security cameras placed in strategic locations; and
• Rated electrical equipment is in use and bonding and grounding of non-
conductive pipework and equipment in the process area reduces the risk of build-
up of static electricity.
In the event of a fire on site, there is the risk that the water used for fire fighting could
become contaminated with chemicals and that this contaminated water could drain into
the ground or, via the surface water system, into the Deans Grange stream. To mitigate
against the risk of this happening, a system has been provided for the containment of
water used for fire fighting. This system has the ability to retain up to 1,750 m3 of
contaminated firewater in dedicated above-ground firewater retention tanks (located to
the south of the site). This system operates by diverting all surface water to retention
tanks upon the initiation of the site fire-pumps.
6. SITE SPECIFIC ELRA
6.1 General
For facilities such as the Pottery Road plant, a detailed site specific ELRA is considered
appropriate.
The objectives of the ELRA are:
� To identify and quantify environmental liabilities at the facility focusing on:
unplanned, but possible and plausible events occurring during the
operational phase;
� To calculate the value of financial provisions required covering unknown
liabilities;
� To identify suitable financial instruments to cover each of the financial
provisions; and
� To provide a mechanism to encourage continuous environmental
improvement through the management of potential environmental risks.
The methodology includes a Risk Management Programme for the mitigation and
management of any environmental liabilities identified at this site. This programme is not
required for the calculation or implementation of a financial provision at a facility.
However, such a programme would encourage continuous environmental improvement
and the reduction of environmental liabilities.
The ELRA will cover environmental risks leading to a potential or anticipated liability.
Environmental risks will be deemed to cover all risks to: surface water, groundwater,
atmosphere, land and human health.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 32
Final
6.2 Methodology-Risk Identification, Likelihood and Consequence
The following steps were undertaken as part of the site specific ELRA;
• Risk Identification
• Risk Classification (includes an Occurrence Assessment and a Severity
Assessment)
• Risk Evaluation
• Risk Prevention/Mitigation
6.2.1 Risk Identification
Risks where reviewed and updated on the site through:
1. What-if analysis - A suggested method of carrying out this process is to initially
identify all the ‘processes’ on site, list the hazards associated with each process,
identify potential causes of failure of the processes and analyze the effect
impacts on the environment.
Table 6.1 Example Hazard Identification Table
Risk ID Potential Hazard Environmental Effect
1 Describe scenario for occurrence
of potential liability e.g. spill of
solvent from solvent storage tank
Describe consequence
of proposed scenario
e.g. spill of solvent
goes to surface water.
6.2.2 Risk Classification-Occurrence Analysis
Having identified the potential risk, the likelihood of its occurrence needs to be assessed.
An analysis of historical data and existing environmental controls as outlined in previous
sections of this report was utilised when estimating likelihood of identified potential risks
occurring at PIP.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 33
Final
The following table defines various likelihoods:
Table 6.2 Risk Classification Table-Occurrence
Rating
/Score
Category Description Likelihood
of
Occurrence
(%)
1 Very Low Very low chance of hazard occurring in 30 yr period 0-5
2 Low Low chance of hazard occurring in 30 yr period 5-10
3 Medium Medium chance of hazard occurring in 30 yr period 10-20
4 High High chance of hazard occurring in 30 yr period 20-50
5 Very High Very high chance of hazard occurring in 30 yr period >50
6.2.3 Risk Classification-Severity Assessment
Once the environmental impact had been identified one of the following consequences is
assigned.
Table 6.3 Risk Classification Table-Severity Criteria
Rating
/Score
Category Description Cost of
Remediation
(€)Note 1
1 Trivial No damage or negligible change to the
environment
<10,000
2 Minor Minor impact/localised or nuisance 10,000-100,000
3 Moderate Moderate damage to the environment 100,000-500,000
4 Major Severe damage to the environment 500,000-
1,000,000
5 Massive Massive damage to a large area, irreversible in
medium term
>1,000,000
Note 1 – Costs specific to PIP
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 34
Final
In order to determine an appropriate cost range for each of the Severity scores above,
the following aspects were considered:
• the sensitivity of the receiving environment;
• the anticipated damage that would realistically be expected to occur as a result
of an incident occurring at the site; and
• current anticipated costs associated with remediation and clean up of
environmental liabilities.
As per the EPA Guidance document, environmental risks will be deemed to cover all risks
to: surface water, groundwater, atmosphere, land and human health. In categorising the
severity of an event and therefore the cost of its remediation, one of the most significant
costs (i.e. the one which can prove most difficult to fix a maximum anticipated financial
provision) are costs associated with the remediation of effects on Human Health.
Based on the above considerations it is felt that the cost of remediation for the various
severity categories outlined in Table 6.3 are appropriate and specific to the Pfizer site on
Pottery Road.
Important: When categorising the Severity Rating relating to a risk, the severity rating
assigned must assume that all current mitigation measures in place have failed to prevent
the environmental discharge to the environment, e.g. if assigning an severity rating to a
failure in a storage tank resulting in contamination of surface water, the severity rating is
based on the assumption that the material contained in the storage tank has discharged
to surface waters, i.e. all mitigation measures employed to prevent that failure resulting in
contamination of surface water have failed, i.e. bund failure has occurred, surface water
diversion system, etc.
6.2.4 Risk Evaluation
Having identified the hazard and decided on its likelihood and severity the significance of
the risk is assigned. A risk score is determined by multiplying the occurrence score by the
severity score. The risk scores can be tabulated in a risk matrix.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 35
Final
V. High 5
High 4
Medium 3
Low 2
Occurr
ence
V. Low 1
1 2 3 4 5
T
rivia
l
Min
or
Modera
te
Majo
r
Massiv
e
Severity
Where:
• Red – These are considered to be high-level risks requiring priority attention.
These risks have the potential to be catastrophic and as such should be
addressed quickly.
• Amber / Yellow – These are medium-level risks requiring action, but are not as
critical as a red coded risk.
• Green (light and dark green) – These are lowest-level risks and indicate a need
for continuing awareness and monitoring on a regular basis. Whilst they are
currently low or minor risks, some have the potential to increase to medium or
even high-level risks and must therefore be regularly monitored and if cost
effective mitigation can be carried out to reduce the risk even further this should
be pursued.
For all risks (‘high’, ‘medium’ or ‘low’) an insurance policy or other financial instrument
must be put in place to cover any liabilities.
With regard to ‘medium’ and ‘high’ risks the licensee must detail in the ELRA how these
risks will be made ‘acceptable’.
With regard to liabilities that are not covered by insurance, or other financial instrument,
the licensee must indicate how these liabilities will be underwritten in the future.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 36
Final
6.2.5 Risk Prevention/Mitigation
Where appropriate, and particularly where risks may be in the Amber/Yellow or Red
zones in the Risk Matrix, mitigation measures are assigned to each risks and each Risk
Score is revised using post-mitigation severity and occurrence rankings. The risks are
then re-ranked and tabulated in the risk matrix to illustrate the overall degree of risk
reduction resulting from the risk mitigation measures. Where appropriate, the mitigation
measures are accepted for implementation. A Risk Management Programme is then
prepared which allocates a Risk owner for the ongoing management of risks and the
implementation of risk mitigation measures. Timeframes are also allocated for the
implementation of each risk mitigation measure.
6.3 Identification of Risks at PIP
The risk register has been updated based on observations gathered during the original
site visit along with URS’ extensive knowledge of the site and utilizing information
supplied by PIP, all of the ‘processes’ on site were identified. The hazards associated
with each process were listed and any potential causes of failure of the processes were
identified. If any effect to the environment could be perceived from the failure the effect
was analyzed and this became a Risk. A Risk Register was developed which contained
all the Risks identified on site.
Each process was considered separately and a ‘what if’ analysis was utilized to identify
all reasonable risks which were associated with the process in question. A list of risks
was developed and these were entered into a Risk Register. Table 6.4 illustrates the Risk
Register.
Table 6.4 PIP Risk Register
Risk
ID
Description
1 A spill occurring during the delivery and loading/unloading of bulk diesel oil
2 A spill in transferring diesel oil from bulk storage to Pump House fire pump tanks
3 A spill occurring during the delivery and loading/unloading of drummed virgin
chemicals and waste chemicals (e.g., organic non-chlorinated solvents or
chloroform)
4 A spill occurring during the delivery and loading or unloading of bulk acids or
caustic
5 A failure of one of the bulk diesel storage tanks
6 A failure of one of the bulk acid/caustic storage tanks
7 Loss of integrity of bunds surrounding the diesel tanks
8 Loss of integrity of bunds surrounding the caustic/acid tanks
9 Loss of integrity of storage yards where organic solvents are kept
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
Page 37
Final
Risk
ID
Description
10 Loss of integrity of large external storage cabinets where chloroform and
chloroform contaminated waste is kept
11 Detection of additional TCE contamination on or off site
12 Detection of ground or groundwater contamination from other contaminants
13 Misclassification of waste.
14 Uncontrolled release of chloroform vapour to atmosphere.
15 Generation of fugitive emissions resulting in odour/air pollution.
16 Failure of effluent treatment system resulting in discharge of untreated effluent to
sewer.
17 Failure of underground process or foul drainage network including process or foul
sumps/lift stations resulting in leakage of material into soils and groundwater.
18 An on-site fire/explosion.
19 Spillage of large quantity of materials in production area during material transfer.
20 Release of ozone depleting or global warming substances to atmosphere.
21 Noise generation.
22 Loss of integrity of above ground pipelines conveying substances other than
water where not provided with secondary containment
These risks were assessed against the risk classification tables (RCTs) as provided in
Table 6.2 and 6.3. The risk classification table was designed to reflect the critical levels of
risk appropriate to the PIP site. Ratings, taken from a risk classification table, were
applied to the severity and chance of occurrence of each risk. Table 6.5 below illustrates
the assessment carried out for each risk in terms of its severity and likelihood of
occurrence.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 38
Final
Table 6.5 Risk Assessment
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
1 Spill during
the delivery
and
loading/un
loading of
bulk diesel
oil
Delivery tanker
overturning.
Leak from
delivery tank.
Overflow of
bulk storage
tank during
transfer.
Surface Water
Groundwater or
soil
Contamination.
1 Diesel fuel oil rarely delivered to site
(once every three to four years) since
only used as back up fuel and fire pump
testing.
Security control of deliveries.
Speed restrictions on site roadways
Well demarcated site access roadways
and well maintained.
Staff training in materials handling and
spill control techniques is provided. Spill
kits and SDS’s provided.
Loading and unloading takes place in
designated areas
Provision of a spill diversion and retention
system for storm drainage system
activated by control button and pH alarm.
Level indicators on diesel tanks.
Diesel tanks bunded to minimum 110%
Dedicated standard procedure for bulk
diesel delivery. unloading
4 A large diesel release to soil
or waters would entail
significant clean-up costs
(likely receptors Deans
Grange Stream or soil).
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 39
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
2 A spill in
transferring
diesel oil
from bulk
storage to
Pump
House fire
pump tanks
Overflow of
pump house
storage tank
during
transfer.
Surface Water
Groundwater or
soil
Contamination.
2 1988 incident where diesel oil being
transferred to pump house tanks resulted
in release of diesel oil to Deans Grange
Stream.
Improved control of diesel transfer
procedure in place.
Provision of a spill diversion and retention
system for storm drainage system
activated by control button and pH alarm
Drains from pump house isolated from
main storm drain and so now pump house
effectively internally bunded.
3 The 1988 incident costs not
large. Nonetheless,
significant clean-up
expenditure may be
expected in the event of a
release of diesel oil to
Deans Grange Stream.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 40
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
3 A spill
occurring
during the
delivery
and
loading/unl
oading of
drummed
virgin
chemicals
and waste
chemicals
(e.g.,
organic
non-
chlorinated
solvents or
chloroform)
Drum(s) fall
from delivery
truck.
Leak from
delivery tank.
Drum(s) fall
during transfer
from truck to
storage.
Drum(s) fall
during transfer
to/from areas
of usage.
Surface Water
Groundwater or
soil
Contamination
1 Chemicals,(mainly organic solvents,
cleaning agents and acids/bases)
delivered to site on a daily basis. Staff
training in materials handling and spill
control techniques is provided. Spill kits
and SDS’s provided.
Security control of deliveries.
Speed restrictions on site roadways.
ADR code applies for delivery, loading
and unloading of drummed chemicals.
Drums of solvents and chlorinated waste
shrink wrapped to pallets for
loading/unloading.
Trained forklift drivers.
Well demarcated site access roadways
and well maintained.
Solvents including chloroform, delivered
in drums only.
Large scale bulk storage of solvents not
undertaken.
Provision of a spill diversion and retention
system for storm drainage system
activated by control button and pH alarm.
No recorded previous incidents
3 Based on worst case loss of
a 25 litre drum of
chloroform, migrating to
either Deans Grange
Stream via storm system or
to ground.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 41
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
4 A spill
occurring
during the
delivery
and loading
or
unloading
of bulk
acids or
caustic
Delivery tanker
overturning.
Leak from
delivery tank.
Overflow of
bulk storage
tank during
transfer.
Surface Water
Groundwater or
soil
Contamination.
2 One recorded incident in 30 years: -
delivery tanker arriving on site had a
small bottom outlet valve leak (caustic).
Swift emergency response resulting in
released caustic removed with no
adverse environmental impact.
Security control of deliveries.
Speed restrictions on site roadways
Well demarcated site access roadways
and well maintained.
Staff training in materials handling and
spill control techniques is provided. Spill
kits and SDS’s provided.
Loading and unloading takes place in
designated areas
Provision of a spill diversion and retention
system for storm drainage system
activated by control button and pH alarm.
Level indicators on storage tanks.
Storage tanks bunded to minimum 110%.
3 Based on worst case loss of
acids or caustic, migrating to
either Deans Grange
Stream via storm system or
to ground.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 42
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
5 A failure of
one of the
bulk diesel
storage
tanks
Rupture of
storage tank.
Pinhole leak.
Failure of
piping
attached to the
tank.
Surface Water
Groundwater or
soil
Contamination.
1 All bulk storage tanks are located within
bunded areas; retention capacity is at
least 110% of the largest tank.
Piping joints and valves for tank delivery
lines are within a bunded area.
Provision of a spill diversion and retention
system for storm drainage system
activated by control button and pH alarm.
No recorded failure of AST’s.
4 Currently, there are some
large volume bulk storage
tanks on-site. A large diesel
release to soil or waters
would entail significant
clean-up costs (likely
receptors Deans Grange
Stream or soil).
6 A failure of
one of the
bulk
acid/caustic
storage
tanks
Rupture of
storage tank.
Pinhole leak.
Failure of
piping
attached to the
tank.
Surface Water
Groundwater or
soil
Contamination.
1 All bulk storage tanks are located within
bunded areas; retention capacity is at
least 110% of the largest tanks.
Largest bulk storage tank (for acid &
caustic) is 2.3 m3
Piping joints and valves for tank delivery
lines are within a bunded area.
Provision of a spill diversion and retention
system for storm drainage system
activated by control button and pH alarm.
No recorded failure of AST’s.
3 The volume of acid or
caustic per tank is not very
large. Acid and caustic
contamination would not be
persistent. Nonetheless,
significant clean up costs
could be incurred in event of
larger volume loss (full tank
failure).
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 43
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
7 Loss of
integrity of
bunds
surrounding
the diesel
tanks
Seepage of
spills into
underlying soil
or into external
storm drains
Surface Water
Groundwater or
soil
Contamination.
1 All diesel bunds are re-enforced concrete
and have recently passed the integrity
tests. Bunds are integrity tested every
three years and are visually inspected
weekly at the site. Any spill within the
bunds would be detected and cleaned up.
2 The assumption is that
limited contamination would
occur under two scenarios
(noting a total bund wall
collapse unlikely for re-
enforced concrete)::
1 - If, should a diesel tank
fail, the diesel contained
within the bund would be
pumped to safe temporary
storage, limiting volumes of
diesel to residual quantity
that could reach underlying
soil or external yard areas in
the event of a breach in
bund integrity.
2 – Any small releases, e.g,
a valve drip to water
accumulated in the bund,
could over time contaminate
underlying soil if bund
integrity is breached.
In both cases, the likely
contamination would be very
limited.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 44
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
8 Loss of
integrity of
bunds
surrounding
the acid or
caustic
tanks
Seepage of
spills into
underlying soil
or into external
storm drains
Surface Water
Groundwater or
soil
Contamination.
1 All caustic and acid bunds are re-
enforced concrete and have recently
passed the integrity tests. Bunds are
integrity tested every three years and are
visually inspected weekly at the site. Any
spill within the bunds would be detected
and cleaned up.
2 The assumption is that
limited contamination would
occur under two scenarios
(noting a total bund wall
collapse unlikely for re-
enforced concrete):
1 - If, should an acid or
caustic tank fail, the
released acid or caustic
contained within the bund
would be pumped to safe
temporary storage, limiting
volumes of diesel to residual
quantity that could reach
underlying soil or external
yard areas in the event of a
breach in bund integrity.
2 – Any small releases, e.g,
a valve drip to water
accumulated in the bund,
could over time contaminate
underlying soil if bund
integrity is breached.
In both cases, the likely
contamination would be very
limited.
For in
spec
tion p
urpo
ses o
nly.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 45
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
9 Loss of
integrity of
storage
yards
where
organic
solvents
are kept
Seepage of
spills into
underlying soil
or into external
storm drains
(primarily
during
decanting of
organic
solvents from
UN 208 litre
drums)
Surface Water
Groundwater or
soil
Contamination.
1 Modern re-enforced concrete surface
resistant to chemical attack from
substances stored there.
Weather protection where the organic
solvent decanting station is located.
Yard inspected regularly.
Small quantities of organic solvents
managed in the yard
Staff training in materials handling and
spill control techniques is provided. Spill
kits and SDS’s provided.
2 Considering the low
volumes of organic solvent
used in the yard, and the
fact that a very large
integrity breach any
releases would be limited.
10 Loss of
integrity of
large
external
storage
cabinets
where
chloroform
and
chloroform
contaminat
ed waste is
kept
Seepage of
spills into
underlying soil
or into external
storm drains.
Surface Water
Groundwater or
soil
Contamination.
1 Two storage cabinets - one containing
approximately 12 UN approved 10 litre drums
of Chloroform (used in production in PM1) and
the other containing approximately the same
volume in waste materials contaminated with
chloroform.
Cabinets are well maintained, modern and are
tested for integrity.
Yard and storage cabinets inspected
regularly.
Staff training in materials handling and
spill control techniques is provided. Spill
kits and SDS’s provided.
3 Considering the volumes of
chloroform (120 litres), and
the fact that a very large
integrity may not result in
the total loss of all 12 drums
any releases would be
limited.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 46
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
11 Detection
of
additional
TCE
contaminati
on on or off
site
Human health
or
environmental
risk from
contact with
impacted
environmental
media.
Surface Water
Groundwater or
soil
Contamination.
Impact on
human health.
2 Detection of additional TCE
contamination on or off site is unlikely
considering the detailed investigations
undertaken to identify TCE contamination
from the site.
3 Should additional TCE
contamination be identified,
then the severity score is
based on an assumption
that the contamination would
be less then that detected to
date, coupled with what has
been concluded in
Quantitative Risk
Assessment.
12 Detection
of ground
or
groundwate
r
contaminati
on from
other
contaminan
ts
Human health
or
environmental
risk from
contact with
impacted
environmental
media.
Surface Water
Groundwater or
soil
Contamination.
2
The results of groundwater analysis
completed on the Pfizer site at Pottery
Road indicated a neutral pH and did not
indicate the presence of VOC
contamination.
Many soil and groundwater investigations
undertaken on the Pottery Road site.
There is a historical municipal landfill on
the site and some, albeit minor,
contamination related to the historical
landfill was observed during the pre-
construction phase in 2004 for the Aseptic
Project.
There are no recorded incidents of the
spill or release of chemicals not otherwise
described in this ELRA.
2 Considering the low
volumes of chemicals used
on the site, both currently
and historically, and, with
the exception of chloroform
and TCE, the relatively non-
persistent (in the
environment) properties of
chemicals used, any future
detected contamination is
likely to be limited.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:06
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 47
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
13 Misclassific
ation of
Waste
Improper
disposal of
waste.
Surface Water
Groundwater or
soil
Contamination.
Public Health
Risk if
hazardous
waste is
disposed of in
non-hazardous
manner.
1 All matters and records related to waste
management, are managed by conditions
and schedules contained in the IPPC
licence.
Designated Waste Storage Compound.
DGSA controls in place.
No known issues regarding waste
management.
No persistent pollutants likely in waste
transfers.
4 If a large quantity of waste
was incorrectly categorised,
it could result in significant
financial implications for PIP
14 Uncontrolle
d release of
chloroform
vapour to
atmosphere
Risk to human
health in
surrounding
area
Atmospheric
pollution.
2 There is currently effectively just one
Main Emission, A2-1, on building PM1,
serving the process where chloroform is
used.
There has been one historical ELV
exceedances regarding air emissions of
Chloroform.
Existing monitoring and control
techniques employed at the plant would
shut down the process causing the
emission
1 Unlikely that a large quantity
but severity assumes
material would be emitted.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 48
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
15 Generation
of fugitive
emissions
resulting in
odour/air
pollution
Risk to human
health in
surrounding
area and
odour
nuisance
Atmospheric
pollution
1 Air handling units in place and maintained
on a regular basis in relevant laboratories.
HEPA filtering of production areas.
Waste management system in place.
No biological treatment at the effluent
balancing tanks – pH neutralisation plant.
Fugitive emissions study completed which
concludes that no significant fugitive
emissions at Pfizer.
2 Impact would be limited to
the surrounding area.
Unlikely that a very strong
odour would result from
activities at Pfizer.
Not likely to result in any
significant unknown
liabilities. Odour would
eventually dissipate in the
environment. Not likely to
result in any significant
health effects.
For in
spec
tion p
urpo
ses o
nly.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 49
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
16 Failure of
effluent
treatment
system
resulting in
discharge of
untreated
effluent to
sewer.
Failure of on-
site
neutralisation
tank resulting
in discharge of
untreated
effluent to Dun
Laoghaire
Rathdown
Council Sewer
and
subsequent
release to sea.
Impact on
receiving local
authority
treatment plant
with knock-on
effects in
receiving waters
at Killiney Bay.
2 BMS system in place which raises an
alarm at security if the wastewater
comes within a specific range but
which is also within the IPPCL limit.
Security then notifies the EHS
Manager or Environmental Officer and
the Utility technician on duty who
respond immediately to the alarm.
The BMS is checked each business
day by engineering.
Environmentally critical equipment
related to the balancing system is
maintained on a weekly basis.
PIP Management can cease
discharging from effluent balancing
system if failure occurs.
Further treatment at the Dun
Laoghaire Rathdown Council Sewer
prior to release to sea.
There have been minor non-
compliances with effluent (pH and
flow) and one incident regarding
release of VFEND product (refer to
section 4.2.3)
2 Costs associated with
remediation if hazard
occurred.
Based on experience from
VFEND incident unlikely to
be any significant
environmental impact.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 50
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
17 Failure of
underground
process or
foul drainage
network
including
process or
foul
sumps/lift
stations
resulting in
leakage of
material into
soils and
groundwater
Seepage of
leaks into
underlying
soils and
groundwater.
Surface Water
Groundwater or
soil
Contamination.
2 As per the IPPCL, underground
pipelines are inspected every three
years. A drain integrity survey of
surface, foul and process underground
pipelines was completed in 2009.
Some minor defects in foul drainage
identified and repaired.
3 Severity is based mainly on
potential costs associated
with repair of undergrounds
drains & possible soil
remediation if major
discharge were to occur.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 51
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
18 An on-site
fire/explosion
.
Release of
toxic and
hazardous
material to
atmosphere,
surface water,
groundwater.
Atmospheric,
Surface Water
Groundwater or
soil
Contamination.
1 Comprehensive control systems and
maintenance programme in place to
minimise the risk of fire.
Comprehensive Emergency Response
Plan in place at the site.
All processes, equipment and
techniques used on site are in line with
up-to date manufacturing techniques
used in the industry.
Very high standard of fire protection
and detection at the site.
Surface waters would be diverted to
the firewater retention tank in the
event of fire– therefore contaminated
waters would be retained on site and
so there should be no costs
associated with surface water
remediation.
No known event has occurred on-site.
Good ATEX (explosion protection)
control.
Very small quantities of chemicals on
site with the potential to do significant
harm to the environment in any one
location on the site.
4 Severity costing based on
emissions to ground or
surface water in the event of
a failure to contain a large
volume of contaminated
firewater.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 52
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
19 Spillage of
large quantity
of materials
in production
area during
material
transfer.
Seepage of
spills into
underlying
soils and
groundwater.
Risk to human
health.
Surface Water
Groundwater or
soil
Contamination if
material migrates
outside
production areas
1 Floor drains are directed to the effluent
balancing system.
Staff training in materials handling and
spill control techniques is provided.
Spill kits and MSDS’s provided.
No known incidents have occurred on-
site.
Emergency response procedure
accounts for environmental incidents,
including spills.
3 If large spill were to migrate
beyond existing containment
measures, it would result in
moderate damage to the
environment as moderate
volumes of hazardous/toxic
material could be contained
in production runs may be
released via surface water
drainage system to the
Dean Grange stream.
20 Release of
Ozone
Depleting or
global
warming
substances
to
atmosphere
Ozone
depletion
Atmospheric
pollution
2 HFCs and HCFCs in use on-site,
mainly in fridges, freezers, chillers,
HVAC units and freeze driers, are
tracked in accordance with site
specific procedures. Any loss of
HFCs/HCFCs from the systems are
recorded in a site register and these
figures are used to populate the
PRTR.
1 Negligible effect on the
ozone layer resulting from
PIP activities (102.5kg of
HFC were reported in the
AER for 2009 as losses
accidental losses from the
systems).
Localised impact – potential
health issues and costs
associated with repair of
refrigerant system
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 53
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
21 Noise
Generation
Noise
disturbance in
the
surrounding
area
Noise Pollution 3 Engineering controls in place.
Acoustic louvers in place in
maintenance/utilities.
The pump house has been upgraded
so as to reduce noise levels being
emitted.
Noise survey is conducted annually in
accordance with the IPPCL.
New expansion design with
surrounding berms to lessen off-site
noise impact
2 Localised impact - nuisance
to locals
Costs associated with noise
reduction measures.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 54
Final
Risk
ID
Risk Potential
Hazards
Environmental
Effect
Occurrence
Rating
Basis of Occurrence Severity
Rating
Basis of Severity
22 Loss of
integrity of
above
ground
pipelines
conveying
substances
other than
water where
not provided
with
secondary
containment
Release of
toxic and
hazardous
material to
atmosphere,
surface water,
groundwater.
Surface Water
Groundwater or
Soil
Contamination.
Risk to human
health if
employees under
or near piperack
when failure
occurred.
1 No previous incidents of major pipe
rack failure. Major failure is unlikely to
occur unless an unlikely incident such
as collision with an item of plant on-
site was to occur.
The main pipe rack runs are from the
CUB to production and then only
carrying steam and water. There is no
bulk solvent storage on site and no
solvent pipelines on racks.
Some short runs of diesel pipeline and
caustic/acid/utility treatment chemicals
(at the CUB) exist over unmade
ground. Acid and caustic pipes also
run overground from the bulk storage
tanks to the PM2.
No recorded incidents relating to
release of chemicals from above
ground pipelines.
3 Severity based on costs
associated with clean up of
diesel should a leak from a
diesel pipeline above ground
not be identified. . Any
impact on soil, groundwater
or surface water would be
localised.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 55
Final
6.4 Assessment of Risks at PIP
6.4.1 Risk Register
The risk register below ranks the risks in order of decreasing score to prioritise mitigation
and management measures.
Table 6.6 Risk Register ranked by Risk Score
Risk ID Description Occurrence
Rating
Severity
Rating
Risk Score
2 A spill in transferring diesel
oil from bulk storage to Pump
House fire pump tanks
2 3 6
4 A spill occurring during the
delivery and loading or
unloading of bulk acids or
caustic
2 3 6
11 Detection of additional TCE
contamination on or off site
2 3 6
17 Failure of underground
process or foul drainage
network including process or
foul sumps/lift stations
resulting in leakage of
material into soils and
groundwater.
2 3 6
21 Noise generation. 3 2 6
1 A spill occurring during the
delivery and
loading/unloading of bulk
diesel oil
1 4 4
5 A failure of one of the bulk
diesel storage tanks
1 4 4
12 Detection of ground or
groundwater contamination
from other contaminants
2 2 4
13 Misclassification of waste. 1 4 4
16 Failure of effluent treatment
system resulting in discharge
of untreated effluent to
sewer.
2 2 4
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 56
Final
Risk ID Description Occurrence
Rating
Severity
Rating
Risk Score
18 An on-site fire/explosion. 1 4 4
3 A spill occurring during the
delivery and
loading/unloading of
drummed virgin chemicals
and waste chemicals (e.g.,
organic non-chlorinated
solvents or chloroform)
1 3 3
6 A failure of one of the bulk
acid/caustic storage tanks
1 3 3
10 Loss of integrity of large
external storage cabinets
where chloroform and
chloroform contaminated
waste is kept
1 3 3
19 Spillage of large quantity of
materials in production area
during material transfer.
1 3 3
22 Loss of integrity of above
ground pipelines conveying
substances other than water
where not provided with
secondary containment
1 3 3
7 Loss of integrity of bunds
surrounding the diesel tanks
1 2 2
8 Loss of integrity of bunds
surrounding the caustic/acid
tanks
1 2 2
9 Loss of integrity of storage
yards where organic solvents
are kept
1 2 2
14 Uncontrolled release of
chloroform vapour to
atmosphere.
2 1 2
15 Generation of fugitive
emissions resulting in
odour/air pollution.
1 2 2
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 57
Final
Risk ID Description Occurrence
Rating
Severity
Rating
Risk Score
20 Release of ozone depleting
or global warming
substances to atmosphere.
2 1 2
6.4.2 Risk Matrix
The risk matrix below indicates the critical nature of each risk. (Risk ID’s from the Risk
Register have been used to complete this matrix.)
Table 6.7 – Risk Matrix
V. High 5
High 4
Medium 3 21
Low 2 14, 20 12, 16 2, 4,
11, 17
Occurr
ence
V. Low 1 7, 8, 9,
15
3, 6, 10
19, 22
1, 5,
13, 18
1 2 3 4 5
Trivia
l
Min
or
Modera
te
Majo
r
Massiv
e
Severity
Where:
Red is a high level risk.
Yellow is a medium level risk.
Green (light and dark) is a low level risk.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 58
Final
Table 6.7 above indicates that there are currently no risks identified in the red zone or
yellow zones requiring priority attention. This is a result of existing environmental controls
in place at the site. All risks identified are located in the green zone (light and dark)
indicating that these are currently low risk. However, it is important to note that these
risks are considered low risk as a result of existing controls measures employed at the
site aimed at reducing/eliminating both the occurrence and where this is not possible the
severity of these risks. There is a need for continuing awareness and monitoring of these
risks on a regular basis.
6.5 Risk Prevention, Mitigation and Management
The risk assessment and categorisation phase identified no red or yellow zone risk, which
requires immediate action. All risk were classified in the as green zone risks. Current
measures to control these risks are considered adequate with No further control
measures considered necessary. However, these risks should be monitored on a regular
basis.
However, the green zone risks may have the potential to increase to yellow or red zone
risks, and where additional risk management measures are available to manage them at
their current levels or reduce them further, these should be implemented if considered
cost-effective.
6.5.1 Quantification of Unknown Environmental Liabilities
The costs associated with the known environmental liabilities (e.g. closure and aftercare
costs and on-site contamination) for the PIP facility was calculated through the
preparation and costing of the RMP (refer to Site Specific RMP prepared for PIP).
For the unknown liabilities identified in this report a financial model is necessary to
estimate the environmental liability associated with these risks.
Each Risk has two characteristics that are derived from the Risk Classification Tables
(See tables 6.2 and 6.3) that are used in the financial models:
• The range in probability (X-Y%) of the risk occurring
• The range in cost implications (€A-B) if the risk occurs
The requirements of the financial model must first be defined in terms of worst, most
likely or best case scenarios. If the model is for the worst case scenario, then the higher
end of each range is used in the calculations, if the model is for the most likely case then
the median of each range is used and similarly if the best case scenario is required then
the lower end of each range is used resulting in the lowest cost.
The simplest form of financial model can be based on simply multiplying the minimum,
median or maximum value of each range for each Risk (depending on the scenario
considered) and totaling the values for each Risk in the Register.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 59
Final
For the PIP facility the worst case scenario was calculated. Table 6.8 illustrates how the
financial output for the worst case scenario is calculated.
From this, financial instruments for unknown liabilities can be selected as outlined in
Section 8 of this report.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 60
Final
Table 6.8 - Worst Case Scenario Financial Model
Risk
ID
Potential Hazard Occurrence
Rating
Likelihood
of
Occurrence
Range (%)
Severity
Rating
Cost
Range (€)
Worst Case
Likelihood
(%)
Worst
Case
Severity
(€)
Worst Case
Cost (€) Note 1
- Site Closure. - -
- - - -
€1.13million
See note 2
1 A spill occurring during the
delivery and loading/unloading of
bulk diesel oil
1
0 - 5
4 500,000 –
1,000,000 5 1,000,000 50,000
2 A spill in transferring diesel oil
from bulk storage to Pump
House fire pump tanks
2
5 - 10
3 100,000 –
500,000 10 500,000 50,000
3 A spill occurring during the
delivery and loading/unloading of
drummed virgin chemicals and
waste chemicals (e.g., organic
non-chlorinated solvents or
chloroform)
1 0 - 5
3 100,000 –
500,000 5 500,000 25,000
4 A spill occurring during the
delivery and loading or
unloading of bulk acids or
caustic
2 5 - 10
3 100,000 –
500,000 10 500,000 50,000
5 A failure of one of the bulk diesel
storage tanks
1 0 - 5
4 500,000 –
1,000,000 5 1,000,000 50,000
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 61
Final
Risk
ID
Potential Hazard Occurrence
Rating
Likelihood
of
Occurrence
Range (%)
Severity
Rating
Cost
Range (€)
Worst Case
Likelihood
(%)
Worst
Case
Severity
(€)
Worst Case
Cost (€) Note 1
6 A failure of one of the bulk
acid/caustic storage tanks
1 0 - 5
3 100,000 –
500,000 5 500,000 25,000
7 Loss of integrity of bunds
surrounding the diesel tanks
1 0 - 5
2 10,000 –
100,000 5 100,000 5,000
8 Loss of integrity of bunds
surrounding the caustic/acid
tanks
1 0 - 5
2 10,000 –
100,000 5 100,000 5,000
9 Loss of integrity of storage yards
where organic solvents are kept
1 0 - 5
2 10,000 –
100,000 5 100,000 5,000
10 Loss of integrity of large external
storage cabinets where
chloroform and chloroform
contaminated waste is kept
1 0 - 5
3 100,000 –
500,000 5 500,000 25,000
11 Detection of additional TCE
contamination on or off site
2 5 - 10
3 100,000 –
500,000 10 500,000 50,000
12 Detection of ground or
groundwater contamination from
other contaminants
2 5 - 10
2 10,000 –
100,000 10 100,000 10,000
13 Misclassification of waste. 1 0 - 5
4 500,000 –
1,000,000 5 1,000,000 50,000
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 62
Final
Risk
ID
Potential Hazard Occurrence
Rating
Likelihood
of
Occurrence
Range (%)
Severity
Rating
Cost
Range (€)
Worst Case
Likelihood
(%)
Worst
Case
Severity
(€)
Worst Case
Cost (€) Note 1
14 Uncontrolled release of
chloroform vapour to
atmosphere.
2
5 - 10
1
<10,000 10 10,000 1,000
15 Generation of fugitive emissions
resulting in odour/air pollution.
1 0 - 5
2 10,000 –
100,000 5 100,000 5,000
16 Failure of effluent treatment
system resulting in discharge of
untreated effluent to sewer.
2 5 - 10
2 10,000 –
100,000 10 100,000 10,000
17 Failure of underground process
or foul drainage network
including process or foul
sumps/lift stations resulting in
leakage of material into soils and
groundwater.
2 5 - 10
3 100,000 –
500,000 10 500,000 50,000
18 An on-site fire/explosion. 1 0 - 5
4 500,000 –
1,000,000 5 1,000,000 50,000
19 Spillage of large quantity of
materials in production area
during material transfer.
1 0 - 5
3 100,000 –
500,000 5 500,000 25,000
20 Release of ozone depleting or
global warming substances to
atmosphere.
2 5 - 10
1 10,000 –
100,000 10 100,000 10,000
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals Dun Laoghaire ELRA
16 February 2011
Page 63
Final
Risk
ID
Potential Hazard Occurrence
Rating
Likelihood
of
Occurrence
Range (%)
Severity
Rating
Cost
Range (€)
Worst Case
Likelihood
(%)
Worst
Case
Severity
(€)
Worst Case
Cost (€) Note 1
21 Noise generation. 3 10 - 20
2 10,000 –
100,000 20 100,000 20,000
22 Loss of integrity of above ground
pipelines conveying substances
other than water where not
provided with secondary
containment
1 0 - 5
3
100,000 –
500,000 5 500,000 25,000
Total worst case cost of Unknown liabilities (excluding RMP costs, refer Note 2) 596,000
Note 1: The financial provision was estimated using the guidance document provided by the EPA. It is noted that this is an estimated cost potential
based on estimated probability of a risk occurring and estimated magnitude of any resulting environmental liability. It is the opinion of URS that
liabilities in excess of the total shown on the table above could conceivably occur and that consequently financial provision in excess of this figure
is maintained by the site.
Note 2: The costs associated with a closure of the facility are dealt with in the Residuals Management Plan (updated in February 2011) along with
details of the financial provisions in place to deal with this.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Page 64
Final
7. FINANCIAL PROVISIONS
In the preceding sections we have summarised the site sensitivity, known historic
environmental liabilities and the measures, both technical and managerial, currently in
place to eliminate/reduce the risk of new environmental liabilities arising.
It has been concluded that the site environmental and safety management system is
robust in terms of preventing the development of any new significant off-site
environmental liability.
In the following section, we discuss the financial provisions at the site and whether these
provisions are adequate to satisfactorily address the liabilities addressed in Section 6.
7.1 Current Financial Provisions
Pfizer Ireland Pharmaceuticals, Dun Laoghaire (Pfizer Dun Laoghaire) is a component
site of Pfizer Ireland Pharmaceuticals, which operates within the Pfizer Global Supply
(PGS) division of Pfizer Inc. PGS operates a global network of manufacturing sites,
including both bulk manufacture and final dosage formulation facilities, together with
logistics facilities, and technical support functions. The function of PGS within the Pfizer
Inc. organisation is to ensure the manufacture and supply of quality product to the
company for ultimate distribution to the marketplace.
Pfizer Inc., which is headquartered in New York, discovers, develops, manufactures and
markets leading prescription medicines and healthcare solutions, for humans and
animals. Pfizer Inc. has total consolidated assets of $212 billion (USD) as at 31
December 2009 and consolidated net income in excess of $8.6 billion (USD) for the
financial year ended 31 December 2009. The company is the world’s largest
pharmaceutical company and recorded global revenues of US$67.8 billion in 2010.
The Pfizer Dun Laoghaire site is a cost centre within PGS and is therefore centrally
funded from Pfizer headquarters in the US. The site operates to an agreed annual
budget which is set in advance and which is intended to cover projected expenditure
related to site operations for that financial year.
In common with many multinational companies, PIP maintains a global public liability
insurance providing indemnity in respect of legal liabilities arising from, for example,
immediate, sudden and unforeseen discharge consequent upon an accident or due to
defective drains, sewers or sanitary arrangements. The aggregate limit set for
environmental liabilities in this respect is US$10,000,000 with no sub-limits for any
particular type of claim and no requirement for Pfizer to assume any proportion of the
costs before the indemnity applies.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Page 65
Final
The risks identified in the site-specific ELRA are most likely to arise from particular
discrete and essentially sudden incidents such as fire, explosion, spillage, equipment
failures, and process malfunctions. Such incidents would be detected by plant systems
and would therefore be known events. Any potential environmental damage or
contamination arising from such incidents would therefore be covered by the existing
insurance arrangements. The current level of indemnity is more than adequate to cover
the worst-case scenario financial model in the ELRA.
A discovery and confirmation of previously unknown environmental liabilities arising from
gradually operating causes would be characterised and the costs of remediation would be
estimated. Any required remediation would be funded centrally by Pfizer in a similar
manner to that for RMP-associated costs. A scope of remediation work would be defined
and developed, and a dossier then prepared for Pfizer central management. If approved,
central funding would be released to cover the defined work. The release of funds may
be structured as required to cover immediate and short-term activities, and if necessary,
funds may be released over more extended time periods to cover longer-term
requirements, for example over several years or as required.
On the assumption that the risks in the worst-case scenario financial model defined in the
site-specific ELRA, were to give rise exclusively to previously unknown environmental
liabilities to be discovered at a future time (which is highly unlikely), then it is considered
that the worst-case costs of these unknown liabilities would be adequately covered by
Pfizer central funding as described.
Pfizer reviews its insurance and financial arrangements on a regular basis for its ongoing
and continued adequacy. Any changes or updates to such arrangements shall be
described in ELRA reviews to be submitted to the Agency.
7.2 Assessment of Pfizer Financial Provision
The environmental liabilities identified and assessed in this report (refer to Section 6) are
in the main unforeseen or unanticipated events that could occur suddenly as a result of
an accident or failure of control systems. Other liabilities identified are the result of
gradual and unforeseen discharge consequent upon failure of control systems which may
result in a discharge to the environment such as leaking drains or undetected leaks in
piperack systems.
Having consideration for the worst-case costs calculated in Table 6.8, a comparison of
existing financial provisions presented in Section 7.1 above may be made with the type of
unknown liabilities identified at the site.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:07
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Page 66
Final
Table 7.1 – Assessment of Pfizer Financial Provision
Risk Type Existing Pfizer Financial
Provision
Comment
Immediate, sudden and
unforeseen discharge
consequent upon an
accident.
Pfizer Global Insurance Pfizer Insurance coverage
financially adequate to cover
any liabilities identified.
Gradual unforeseen
discharge consequent upon
failure of control systems.
Pfizer Central Funds This type of Financial
Provision is adequate to
cover any unknown liabilities
which may arise but which
may not be covered under
the existing Pfizer Global
insurance.
Closure Restoration and
Aftercare Liabilities
Pfizer Central Funds Pfizer have already used
this to decommission and
remediate other sites and
facilities and it is deemed an
adequate financial provision
instrument to cover the
associated costs.
Based on the assessment of the current financial provisions in place, it is considered
unlikely that Pfizer requires any additional financial provisions beyond those currently
employed by the site as detailed in Section 7.1.
A statement of Parent Company Financial Guarantee by Pfizer Inc., approved by the EPA
in January 2011, is presented in Appendix B.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Page 67
Final
8. LIMITATIONS
URS Ireland Limited (URS) has prepared this Report for the sole use of Pfizer Ireland
Pharmaceuticals in accordance with the Agreement under which our services were
performed. No other warranty, expressed or implied, is made as to the professional
advice included in this Report or any other services provided by us. This Report may not
be relied upon by any other party without the prior and express written agreement of
URS. Unless otherwise stated in this Report, the assessments made assume that the
sites and facilities will continue to be used for their current purpose without significant
change. The conclusions and recommendations contained in this Report are based upon
information provided by others and upon the assumption that all relevant information has
been provided by those parties from whom it has been requested. Information obtained
from third parties has not been independently verified by URS, unless otherwise stated in
the Report.
9. COPYRIGHT
© This Report is the copyright of URS Ireland Limited. Any unauthorised reproduction or
usage by any person other than the addressee is strictly prohibited.
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Final
Appendix A - Site Plan
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08
FORMER
DEANS GRANGE STREAM(FLOW TO SOUTHEAST)
(CULVERTED)
Iveagh Court, 6-8 Harcourt Road, Dublin 2TEL +353 1 4155100 FAX +353 1 4155101
ENVIRONMENTAL LIABILITY RISK ASSESSMENT,POTTERY ROAD
PROJECT
CLIENT
DRAWING TITLE
DRAWN STATUS CHECKED APPROVED
SML FINAL SF SF/PHSCALE DRG NO.
DATE
AS SHOWN
FEB 2011
49340764/01
FIGURE 2SITE LAYOUT
PFIZER IRELAND PHARMACEUTICALS
PRIVATE AND CONFIDENTIAL
APPROXIMATE SCALE (m)
0 25 50 75 100
Pfizer Site Outlined in Red
True North
Plant North
(CURRENTLY A LANDSCAPE AREA
NOTES
PNTN
TN
PN
EARTHENBERMS
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08
Pfizer Ireland Pharmaceuticals, Pottery Road Environmental Liabilities Risk Assessment 2010 Review
Pfizer Ireland Pharmaceuticals\49340764 Pfizer Pottery Road ELRA 2010\DURP0001/JAG/JAG
16 February 2011
Final
Appendix B - Statement of Parent
Company Financial Guarantee
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08
For
insp
ectio
n pur
pose
s only
.
Conse
nt of
copy
right
owne
r req
uired
for a
ny ot
her u
se.
EPA Export 25-03-2011:03:35:08